Meeting
2022 ASCO Annual Meeting
A first-in-human phase 1 study of the next-generation RET inhibitor, LOXO-260, in RET inhibitor refractory patients with RET-altered cancers (trial in progress).
Authors
Nathan A. Pennell
Department of Hematology and Medical Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH
Nathan A. Pennell , Lori J. Wirth , Justin F. Gainor , Julia K Rotow , Melissa Lynne Johnson , Todd Michael Bauer , Matthias Kroiss , Vineeth Sukrithan , Hyunseok Kang , Francis P. Worden , Christine M. Bestvina , Julien Hadoux , Philippe Alexandre Cassier , Antoine Italiano , Juergen Wolf , Marcia S. Brose , Emin Avsar , Michael D. Axelson , Vivek Subbiah , Alexander E. Drilon
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers
Track
Lung Cancer
Sub Track
Local-Regional Non–Small Cell Lung Cancer
Clinical Trial Registration Number
NCT05241834
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr TPS8595)
DOI
10.1200/JCO.2022.40.16_suppl.TPS8595
Abstract #
TPS8595
Poster Bd #
218b
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
A first-in-human phase I, dose-escalation and dose-expansion study of SY-5007, a highly potent and selective RET inhibitor, in Chinese patients with advanced RET positive solid tumors.
First Author: Caicun Zhou
Poster
2024 ASCO Annual Meeting
A phase-1 dose escalation and expansion study of EP0031, a next-generation selective RET inhibitor (SRI), in patients with SRI-naïve or pretreated advanced RET-altered NSCLC and other tumors.
First Author: Elena Garralda
Poster
2019 ASCO Annual Meeting
A phase I study of BOS172738 in patients with advanced solid tumors with RET gene alterations including non-small cell lung cancer and medullary thyroid cancer.
First Author: Patrick Schoffski
Poster
2021 ASCO Annual Meeting
Selpercatinib efficacy and safety in patients with RET-altered thyroid cancer: A clinical trial update.
First Author: Eric Jeffrey Sherman